Sweet'n Low

From WikiMD's WELLNESSPEDIA

Overview of Sweet'n Low:

```


Sweet'n Low is an artificial sweetener that was first introduced in 1957 by the Cumberland Packing Corporation. It is primarily made from saccharin, a substance that is 300 to 500 times sweeter than sugar but has no caloric value.

History[edit]

Sweet'n Low was first introduced in 1957 by Ben Eisenstadt, the founder of the Cumberland Packing Corporation. Eisenstadt was a diner owner in Brooklyn, New York, who was looking for a way to package sugar in individual servings. He eventually developed the idea for Sweet'n Low, a zero-calorie sweetener that could be used in place of sugar.

Composition[edit]

Sweet'n Low is primarily made from saccharin, a substance that is 300 to 500 times sweeter than sugar but has no caloric value. It also contains dextrose and cream of tartar, and is commonly used in both cooking and baking.

Health Effects[edit]

While Sweet'n Low is a zero-calorie sweetener, there has been some controversy over the potential health effects of saccharin. Some studies have suggested that it may increase the risk of cancer, while others have found no such link. The FDA has stated that saccharin is safe for human consumption.

See Also[edit]

References[edit]


External Links[edit]

```

This article provides a brief overview of Sweet'n Low, its history, composition, and potential health effects. It also includes internal links to related topics such as artificial sweeteners, saccharin, and sugar substitutes.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.